Efficacy and safety profile of roflumilast in a real-world experience

ÇİLLİ A., Bal H., Gunen H.

JOURNAL OF THORACIC DISEASE, cilt.11, sa.4, ss.1100-1105, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 11 Sayı: 4
  • Basım Tarihi: 2019
  • Doi Numarası: 10.21037/jtd.2019.04.49
  • Dergi Adı: JOURNAL OF THORACIC DISEASE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1100-1105
  • Anahtar Kelimeler: Chronic obstructive pulmonary disease (COPD), roflumilast, efficacy, safety, OBSTRUCTIVE PULMONARY-DISEASE, COPD
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Background: Roflumilast is the only phosphodiesterase enzyme 4 inhibitor approved in the treatment of chronic obstructive pulmonary disease (COPD) patients with chronic cough and sputum and a history of exacerbations. Real-world studies about the use of roflumilast are limited. Our aim was to assess the efficacy, safety and tolerability of roflumilast in the treatment of stable COPD, in a real-world setting.